Efficacy and safety comparison of topical loteprednol and topical non-steroidal anti-inflammatory drugs in seasonal allergic conjunctivitis: a prospective open label comparative study

Sheshidhar G. Bannale, Pundarikaksha HP, Sowbhagya HN, Jyothi R, Vijendra R


Background: Seasonal allergic conjunctivitis (SAC) one of the most common ocular immunological disorder affecting wide population. Various classes of drugs are been used to control allergic inflammation. Traditionally topical glucocorticoids have been used for SAC. However, repeated and continuous use of steroids is associated with various complications like increase in intraocular pressure, posterior sub capsular cataract, increased susceptibility for infections and delayed wound healing. Hence the current emphasis is to prefer topical NSAIDs as they are free from various steroid related complications. As there is paucity of information regarding the comparative efficacy of topical steroids and NSAIDs, the present study was taken up. The main objective was to study the comparative efficacy and safety of three topical NSAIDs: flurbiprofen, diclofenac, ketorolac and the topical steroid loteprednol, in SAC.

Methods: A prospective, comparative study enrolled 40 patients for SAC. All study drugs were instilled 4 times daily for 4 weeks. Patients were assessed for objective and subjective parameters of inflammation at baseline and weekly intervals for 4 weeks using four point scales, and also observed for any side effects. The anti-inflammatory action was assessed by the change in mean scores from basal and at various intervals.

Results: Loteprednol was more effective than the three NSAIDs, only ketorolac comparable to loteprednol in relieving ocular itching. Study drugs showed good safety and tolerability, with only minimal local side effects.

Conclusions: SAC the topical steroid loteprednol was found superior to NSAIDs.


SAC, Loteprednol, NSAIDs

Full Text:



Alexander M, Berger W, Buchholz P. The reliability, validity, and preliminary responsiveness of the eye allergy patient impact questionnaire(EAPIQ). Health Qual Life Outcomes. 2005;3:67.

Singh K, Bielory L. Epidemiology of ocular allergy symptoms in United states adults (1988-1994). Proceedings of American allergy asthma and immunology annual meeting, Philadelphia. Ann Allergy Asthma Immunol. 2007;98:22.

Rosa ML, Lionetti E, Reibaldi M, Russo A, Longo A, Leonordi S, et al Allergic conjunctivitis: a comprehensive review of the literature. Italian Journal of Pediatrics. 2013;39:18.

Bielory L, Friedlaender MH. Allergic Conjunctivitis. Immunol Allergy Clin North Am. 2008;28:43-58.

Ackerman S, Smith LM, and Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management Ther Adv Chronic Dis. 2016;7(1):52-67.

Keziah N. Malu. Allergic conjunctivitis in Jos-Nigeria. Niger Med J. 2014;55(2):166-70.

Biswas J, Saha I, Debabrata D, Bandyopadhyay S, Ray B, Biswas G. Ocular morbidity among children at a tertiary eye care hospital in Kolkata, West Bengal. Indian J Public Health. 2012;56(4):293-6.

Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N. The economic and quality of life impact of seasonal allergic conjunctivitis. Ophthalmic epidemiol. 2005;12:233-42.

Yaylali V, demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmologica Scandinavica. 2003;81(4):378-2.

Chensue SW, Ward PA. Inflammation. In: Anderson’s pathology. 10th ed. Damjanov I, Linder J.editors. New York: Anne S Patterson; 1996:387-415.

Larsen GL, Henson PM. Mediators of Inflammation. Annual review of Immunology. 1983;1:335-59.

Edward L, Hower Jr. Basic mechanism in pathology. Inflammation. In: Ophthalmic Pathology an Atlas and Textbook. Spencer WH, Font RL, Green WR, Howes EL, Jakobiec FA, Zimmerman LE. 3rd edition. Philadelphia: WB Saunder Company;1996:1-108.

Burke A, Smyth E, Fitzgerald GA. Analgesic antipyretic agents. In: Goodman and Gillman’s Pharmacological Basis of Therapeutics, 11th ed. Brunton LL editor. New Delhi: McGrew Hill; 2006:671-716.

Joseph Colin. The role of NSAIDs in the management of postoperative inflammation. Drugs. 2007;67(9):1291-308.

Swamy BN, Chilov M, McClellan K, Petsoglou C. Topical Non-steroidal anti-inflammatory drugs in allergic conjunctivitis, meta-analysis of randomized trial data. Ophthalmic Epidemiology. 2007;14:311-9.

Pavesion CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. British Journal of Ophthalmology. 2008;92:455-9.

Awan MA, Agarwal PK, Watson DG, McGhee Charles NJ, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humor and its therapeutic significance. British Journal of Ophthalmology. 2009;33:708-13.

Noble S, Goa KL. Loteprednol etabonate Clinical potential in the management of ocular inflammation. Biodrugs. 1998;10(4):329-39.

Ilyas H, Slonium CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Journal of Eye and Contact Lens. 2004;30(1):10-3.